Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis. (December 2019)

• Record Type: Journal Article
• Authors: Klingel, Reinhard; Heigl, Franz; Schettler, Volker; Roeseler, Eberhard; Grützmacher, Peter; Hohenstein, Bernd; Vogt, Anja; Fassbender, Cordula; Heibges, Andreas; Julius, Ulrich
• Is Part Of: Atherosclerosis. Volume 40(2019)
• Page Start: 17
• Page End: 22
• Publication Date: 2019-12
• Subjects: Atherosclerosis -- Lipoprotein(a) -- Lipoprotein apheresis; Atherosclerosis -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Periodicals; 616.136
• DOI: 10.1016/j.atherosclerosissup.2019.08.037
• Languages: English
• ISSNs: 1567-5688

Abstract

Abstract: Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and a predictor of incident or recurrent cardiovascular events. Although Lp(a) was first described as early as 1963, only the more recent results of epidemiological, molecular, and genetic studies have led to this unequivocal conclusion. More than 20% of Western populations have elevated Lp(a) values. Lp(a) concentrations should be always part of the lipid profile when ASCVD risk is assessed. However, presence of other risk factors, laboratory findings, medical history and family history must be considered to conclude on its clinical relevance in an individual patient. Early or progressive ASCVD or a familial predisposition are key findings which can be associated with elevated Lp(a). The cholesterol portion contained in Lp(a) is also included in the various methods of LDL-C measurement. To assess proximity to the cardiovascular risk related target value for LDL-C, appropriate correction should be applied when high Lp(a) values are obtained to estimate the LDL-C that can actually be treated by lipid lowering drugs. Initial study data show that antisense oligonucleotides, which selectively decrease apolipoprotein(a), are promising as future treatment options. Currently, lipoprotein apheresis, which has a reimbursement guideline in Germany, is the therapy of choice for patients with Lp(a)-associated progressive ASCVD, with the aim of sustained prevention of further cardiovascular events.